Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Cymabay Therapeutics Inc. (NASDAQ: CBAY).

Full DD Report for CBAY

You must become a subscriber to view this report.


Recent News from (NASDAQ: CBAY)

CymaBay Therapeutics to Participate in Upcoming Investor Conferences
NEWARK, Calif., Nov. 20, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in three upcomi...
Source: GlobeNewswire
Date: November, 20 2018 08:00
CymaBay Therapeutics' (CBAY) CEO Sujal Shah on Q3 2017 Results - Earnings Call Transcript
CymaBay Therapeutics, Inc. (CBAY) Q3 2018 Earnings Conference Call November 6, 2018 4:30 PM ET Executives Dan Menold – Vice President-Finance Sujal Shah – Chief Executive Officer Pol Boudes – Chief Medical Officer Chuck McWherter – Chief Scientific O...
Source: SeekingAlpha
Date: November, 06 2018 23:04
CymaBay Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Conference call and webcast today at 4:30p.m. ET NEWARK, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY) a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announ...
Source: GlobeNewswire
Date: November, 06 2018 16:10
CymaBay to Report Third Quarter 2018 Financial Results on Tuesday, November 6
NEWARK, Calif., Oct. 30, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live aud...
Source: GlobeNewswire
Date: October, 30 2018 16:05
CymaBay launches late-stage study of seladelpar in PBC; shares up 2%
CymaBay Therapeutics ( CBAY +2.1% ) initiates a Phase 3 clinical trial, ENHANCE , evaluating seladelpar in patients with primary biliary cholangitis (PBC) who have not responded adequately to or are intolerant of standard first-line ursodeoxycholic acid. More news on: CymaBay Therap...
Source: SeekingAlpha
Date: October, 30 2018 10:39
CymaBay Announces the Initiation of the Seladelpar Global Phase 3 Registration Study (ENHANCE) for the Treatment of Primary Biliary Cholangitis and Additional Corporate Updates
Phase 3 patient enrollment commenced with multiple investigational sites in the U.S. initiated Team expanded with key hires focused on delivering a high-quality registration package NEWARK, Calif., Oct. 30, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), today a...
Source: GlobeNewswire
Date: October, 30 2018 08:00
CymaBay Therapeutics (CBAY) Presents At Rodman & Renshaw.C. Wainwright 20th Annual Global Investment Conference - Slideshow
The following slide deck was published by CymaBay Therapeutics in conjunction with this Read more ...
Source: SeekingAlpha
Date: September, 06 2018 15:00
Is There A Cure For NASH On The Horizon?
Overview of NASH market Non-alcoholic Steatohepatitis ((NASH)) is a devastating type of non-alcoholic fatty liver disease. The current market for NASH is $600 million but by 2026 is estimated to be between $25-39 Billion . Currently, there is no approved therapy that is specific for treat...
Source: SeekingAlpha
Date: September, 05 2018 11:00
Genkyotex advancing PBC candidate GKT831, Phase 2 data readout in coming months
French biotech Genkyotex announces the completion of enrollment 90 subjects necessary for an interim analysis in its Phase 2 clinical trial evaluating lead candidate GKT831 in patients with primary biliary cholangitis (PBC). Preliminary results, expected this fall, will be assessed when pa...
Source: SeekingAlpha
Date: August, 27 2018 13:01
CymaBay Therapeutics to Participate in Upcoming Investor Conferences in August and September
NEWARK, Calif., Aug. 14, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in upcoming inv...
Source: GlobeNewswire
Date: August, 14 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-138.778.5858.778.38796,380
2018-12-128.828.879.038.77301,403
2018-12-118.918.668.948.63285,129
2018-12-108.638.7558.768.325358,952
2018-12-078.628.578.798.46275,684

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1355,864550,74210.1434Cover
2018-12-1233,72166,23450.9119Short
2018-12-1157,996149,93038.6821Short
2018-12-1058,321115,89150.3240Short
2018-12-0735,70773,51248.5730Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CBAY.


About Cymabay Therapeutics Inc. (NASDAQ: CBAY)

Logo for Cymabay Therapeutics Inc. (NASDAQ: CBAY)

Not available

 

Contact Information

 

 

Current Management

  • Sujal Shah / CFO

Current Share Structure

  • Market Cap: $682,715,936 - 05/14/2018
  • Authorized: 100,000,000 - 09/30/2013
  • Issue and Outstanding: 58,501,794 - 02/28/2018

 


Recent Filings from (NASDAQ: CBAY)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 08 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 20 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 20 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 20 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 15 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: March, 15 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: February, 16 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018

 

 


Daily Technical Chart for (NASDAQ: CBAY)

Daily Technical Chart for (NASDAQ: CBAY)


Stay tuned for daily updates and more on (NASDAQ: CBAY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CBAY)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CBAY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CBAY and does not buy, sell, or trade any shares of CBAY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/